Company Product Description Indication Status
Ascentage Pharma Group International, of Suzhou, China, APG-2575 Bcl-2 inhibitor Waldenström macroglobulinemia FDA granted orphan drug designation
Bioaegis Therapeutics Inc., of Morristown, N.J. Rhu-pGSN Recombinant human plasma gelsolin COVID-19 Received clearance from the Spanish Agency for Medicines and Health Products for phase II study in hospitalized patients with severe COVID-19 pneumonia
Boehringer Ingelheim International GmbH, of Ingelheim, Germany Nintedanib  Tyrosine kinase inhibitor Chronic fibrosing interstitial lung diseases with a progressive phenotype beyond idiopathic pulmonary fibrosis  European Commission approved the additional indication
Glaxosmithkline plc, of London Belantamab mafodotin  Antibody-drug conjugate targeting B-cell maturation antigen Relapsed or refractory multiple myeloma FDA's Oncologic Drugs Advisory Committee voted 12-0 that the benefit of the treatment outweigh the risks for use after at least 4 prior therapies including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody
Knopp Biosciences LLC, of Pittsburgh KB-3061 Activator of voltage-gated Kv7.2/7.3 potassium channels KCNQ2 epileptic encephalopathy FDA granted rare pediatric disease designation
Lintonpharm Co. Ltd., of Guangzhou, China  Catumaxomab T-cell engaging bispecific antibody Peritoneal carcinomatosis China’s NMPA cleared the start of a phase III trial
Neoimmunetech Inc., of Rockville, Md. NT-I7 (efineptakin alfa) Long-acting human IL-7 Mild COVID-19 FDA cleared the IND for a phase I study
Oramed Pharmaceuticals Inc., of New York ORMD-0801 Oral insulin Diabetes Based on an end-of-phase II meeting with the FDA, the company plans to run 2 concurrent phase III studies

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments